Adrenal Tumors - Pathogenesis and Therapy

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2015 by University of Wuerzburg
Sponsor:
Collaborators:
Deutsche Krebshilfe e.V., Bonn (Germany)
German Federal Ministry of Education and Research
Information provided by (Responsible Party):
Martin Fassnacht, University of Wuerzburg
ClinicalTrials.gov Identifier:
NCT00669266
First received: April 28, 2008
Last updated: September 6, 2015
Last verified: September 2015
  Purpose
The pathogenesis of adrenal tumors is still not fully elucidated and the treatment options for malignant tumors are poor. The current study investigates different aspects of the pathogenesis of adrenal tumors and evaluates different therapeutic options in patients with adrenocortical carcinoma.

Condition
Adrenal Tumors
Adrenocortical Carcinoma
Cushing Syndrome
Conn Syndrome
Pheochromocytoma

Study Type: Observational
Study Design: Observational Model: Case Control
Official Title: Investigation of the Tumorigenesis of Adrenal Tumors and Evaluation of New Therapeutic Options - Untersuchungen Zur Tumorgenese Von Nebennierentumoren Und Evaluation Neuer Therapieoptionen

Resource links provided by NLM:


Further study details as provided by University of Wuerzburg:

Biospecimen Retention:   Samples With DNA
Germline DNA Tumor samples Serum Plasma Urine

Estimated Enrollment: 500
Study Start Date: September 2002
Estimated Study Completion Date: December 2024
Estimated Primary Completion Date: December 2022 (Final data collection date for primary outcome measure)
Groups/Cohorts
Tumor
Tumor material and corresponding biosamples from patients with adrenal tumors
control group
Biomaterial from patients without adrenal tumor

  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with adrenal tumors
Criteria

Inclusion Criteria:

  • adrenal tumor detected by imaging

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00669266

Contacts
Contact: Martin Fassnacht, MD 49-931-201-36507 fassnacht_m@medizin.uni-wuerzburg.de

Locations
Germany
University of Wuerzburg Recruiting
Wuerzburg, Germany, 97080
Contact: Martin Fassnacht, MD       fassnacht_m@medizin.uni-wuerzburg.de   
Contact: Stefanie Hahner, MD       hahner_s@medizin.uni-wuerzburg.de   
Principal Investigator: Martin Fassnacht, MD         
Sponsors and Collaborators
University of Wuerzburg
Deutsche Krebshilfe e.V., Bonn (Germany)
German Federal Ministry of Education and Research
Investigators
Principal Investigator: Martin Fassnacht, MD U of Wuerzburg
  More Information

Responsible Party: Martin Fassnacht, Head of Endocrinology, University of Wuerzburg
ClinicalTrials.gov Identifier: NCT00669266     History of Changes
Other Study ID Numbers: Wue-Adrenal-Tumors-92/2002 
Study First Received: April 28, 2008
Last Updated: September 6, 2015
Health Authority: Germany: Ethics Commission

Additional relevant MeSH terms:
Syndrome
Adrenocortical Carcinoma
Pheochromocytoma
Cushing Syndrome
Adrenal Gland Neoplasms
Hyperaldosteronism
Disease
Pathologic Processes
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adrenal Cortex Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Adrenal Cortex Diseases
Adrenal Gland Diseases
Endocrine System Diseases
Paraganglioma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Adrenocortical Hyperfunction
Epinephrine
Racepinephrine
Epinephryl borate
Adrenergic alpha-Agonists
Adrenergic Agonists

ClinicalTrials.gov processed this record on August 25, 2016